Genevoyager (Wuhan) Co., Ltd. (Genevoyager) is a leading provider of one-stop CRO/CDMO services for gene therapy products. With a proprietary technology platform for large-scale AAV production and cGMP facilities, Genevoyager is dedicated to advancing healthcare by supporting its partners to develop safe, effective, affordable, and accessible AAV gene therapy products to address unmet medical needs.

The company boasts a highly skilled team of 300 professionals, covering expertise in viral vector research and development, preclinical efficacy evaluation, CMC development, QA/QC, and GMP production. Genevoyager's cGMP facility in Jiangxia District, Wuhan spans 68,000ft2 and encompasses 5 viral vector production lines and 1 fill & finish line. The facility commenced operations in October 2023 and has facilitated the completion of multiple project deliveries. 

Genevoyager possesses a proprietary insect baculovirus system known as One-Bac 4.0. This system employs a novel approach for regulating AAV expression cassettes, coupled with critical process optimizations. It attains higher yield, better infectivity, and higher full-capsid ratio for large-scale manufacturing. The single-batch production capacity of the One-Bac 4.0 system can reach up to 1E+18 vg.

Our subsidiary, BrainVTA (Wuhan) Co., Ltd. (BrainVTA), is a Contract Research Organization (CRO) company that has been delivering innovative viral reagents and customized technical services since 2014. BrainVTA has established itself as a leader in the academic market, dedicated to enhancing the human condition through advancements in biotechnology.